Sign in
CH

CVS HEALTH Corp (CVS)·Q2 2025 Earnings Summary

Executive Summary

  • CVS delivered Q2 2025 adjusted EPS of $1.81 and total revenues of $98.9B, with revenue growth across all segments; adjusted AOI rose 1.7% year over year, while GAAP EPS fell to $0.80 due to $833M in litigation charges .
  • Results beat Wall Street consensus: Adjusted EPS $1.81 vs $1.46*, and revenue $98.9B vs $94.6B*; Q1 also beat on EPS ($2.25 vs $1.67*) and revenue ($94.1B vs $93.6B*) .
  • Guidance raised: FY2025 adjusted EPS to $6.30–$6.40 (from $6.00–$6.20), CFO raised to ≥$7.5B (from ~$7.0B), while GAAP EPS lowered to $3.84–$3.94 (from $4.23–$4.43) .
  • HCB (Aetna) recovery continued (AOI up ~40% y/y; MBR 89.9%), while Health Services AOI declined on client price improvements and Oak Street pressure; Pharmacy & Consumer Wellness (PCW) posted strong volume and same-store growth .
  • Catalysts: Guidance raise and Aetna momentum; offsets include legacy litigation charges and ongoing Oak Street medical cost pressure .

What Went Well and What Went Wrong

What Went Well

  • Aetna margin recovery and execution: HCB adjusted operating income up 39.4% y/y to $1.308B; management emphasized margin recovery and operational improvements using technology to reduce friction and elevate service .
  • Strong retail pharmacy performance: PCW adjusted operating income up 7.6% y/y to $1.338B; same-store pharmacy sales +18.1% and prescription volumes +6.4% on a 30-day basis . “PCW delivered another strong quarter despite persistent reimbursement pressures” — David Joyner .
  • Strategic innovation and AI: CVS committed $20B over the next decade to transform healthcare, including Aetna Care Paths and AI-driven clinical tools; nurses gain up to 90 minutes/day with AI summaries .

What Went Wrong

  • Litigation charges impacted GAAP results: $833M legacy litigation charges lowered operating income and GAAP EPS; Omnicare False Claims Act penalties ($542M) and PBM DIR reporting ($291M) were recorded in Q2 .
  • Health Services margin pressure: Adjusted operating income declined 17.8% y/y to $1.575B due to continued pharmacy client price improvements and elevated MBR at Oak Street .
  • Group MA premium deficiency reserve: $471M PDR recorded amid elevated utilization, lifting HCB MBR to 89.9% (+30 bps y/y); medical membership decreased 358K sequentially, reflecting individual exchange declines .

Financial Results

Consolidated Performance (oldest → newest)

MetricQ4 2024Q1 2025Q2 2025
Total revenues ($USD Billions)$97.710 $94.588 $98.915
Operating income ($USD Billions)$2.368 $3.374 $2.381
Adjusted operating income ($USD Billions)$2.728 $4.579 $3.808
GAAP diluted EPS ($)$1.30 $1.41 $0.80
Adjusted EPS ($)$1.19 $2.25 $1.81

Segment Performance (oldest → newest)

SegmentQ2 2024 Revenues ($B)Q2 2024 Adj OI ($B)Q1 2025 Revenues ($B)Q1 2025 Adj OI ($B)Q2 2025 Revenues ($B)Q2 2025 Adj OI ($B)
Health Care Benefits$32.475 $0.938 $34.810 $1.993 $36.258 $1.308
Health Services$42.171 $1.915 $43.462 $1.603 $46.453 $1.575
Pharmacy & Consumer Wellness$29.838 $1.243 $31.912 $1.313 $33.581 $1.338

KPIs (oldest → newest)

KPIQ4 2024Q1 2025Q2 2025
HCB Medical Benefit Ratio (%)94.8 87.3 89.9
HCB Medical membership (Total, millions)27.095 27.079 26.721
HCB Days claims payable (days)44.0 43.2 40.9
Health Services pharmacy claims processed (millions)499.4 464.2 469.0
PCW prescriptions filled (millions)445.9 435.5 438.1
Same-store pharmacy sales (%)13.0 17.7 18.1
Same-store front-store sales (%)(1.2) (0.3) 3.4
Same-store prescription volume (%)5.9 6.7 6.4

Results vs Estimates (S&P Global)

MetricQ1 2025Q2 2025
Adjusted EPS actual ($)2.25 1.81
Primary EPS Consensus Mean ($)1.673*1.461*
Revenue actual ($USD Billions)94.068 98.428
Revenue Consensus Mean ($USD Billions)93.561*94.594*

Values with an asterisk are retrieved from S&P Global.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
GAAP diluted EPSFY 2025$4.23–$4.43 $3.84–$3.94 Lowered
Adjusted EPSFY 2025$6.00–$6.20 $6.30–$6.40 Raised
Cash flow from operationsFY 2025~$7.0B ≥$7.5B Raised
Total revenuesFY 2025N/A≥$391.5B (company added) New disclosure
HCB adjusted operating income (low end)FY 2025Not disclosed$2.42B at low end; +$500M vs prior Raised (~$500M)
Health Services adjusted operating incomeFY 2025Not disclosed≥$7.34B Lowered (~$200M)
PCW adjusted operating incomeFY 2025Not disclosed≥$5.68B Raised (~$200M)
HCB MBR (low end of AOI range)FY 2025Not disclosed~91% New disclosure
Quarterly dividendNext payment$0.665 per share declared (paid Aug 1) —Maintained

Earnings Call Themes & Trends

TopicQ4 2024 (Q-2)Q1 2025 (Q-1)Q2 2025 (Current)Trend
AI/technology initiativesRestructuring focus; limited AI detail Bundled prior auth for cancer; Clinical Collaboration program $20B decade-long transformation; Aetna Care Paths and AI tools to simplify care Accelerating investment
GLP-1 managementN/APrefer Wegovy July 1; CVS Weight Management program 95% eligible member adoption of preferred formulary; cost competition Scaling and cost containment
Aetna margin recoveryElevated MBR/stars headwinds AOI up sharply; MBR down to 87.3% AOI +39% y/y; MBR 89.9% with $471M group MA PDR Recovery with cautious trend
Oak Street / Health DeliveryHigher health care costs pressure HSS AOI +17.6% y/y; delivery volumes improving Oak Street pressured by higher MBR; Signify strong Continued pressure at Oak
Retail reimbursement modelStore optimization Commercial contracts transitioned to Cost Manage; strong PCW volumes Transition of government business to cost-based pricing in 2026; same-store strength Moving to cost-based models
Regulatory/legalRestructuring charges, opioid accrual Omnicare litigation charge in Q1 $833M legacy litigation charges (Omnicare penalties; PBM DIR) Elevated legal risk

Management Commentary

  • “What people want most — a connected, simpler health care experience — is what CVS Health uniquely provides… Our strong performance demonstrates the continued focus we have on operational and financial improvement across our businesses, led by a significant and durable recovery at Aetna, strong retention at CVS Caremark and growth and momentum at CVS Pharmacy.” — David Joyner, President & CEO .
  • “We are encouraged by a second consecutive quarter of solid 2025 results, while we continue to navigate a dynamic environment… focused on delivering on our financial commitments and advancing initiatives that create long-term value.” — Brian Newman, CFO .
  • “We committed $20 billion to support our transformation of healthcare… deliver a better healthcare experience with reduced friction, greater visibility, and a stronger partnership with doctors and hospitals.” — David Joyner .
  • “We are delivering on our commitments to clients… managing trend remains the most important focus… we took a significant step to create competition among manufacturers to lower costs in GLP-1s, with >95% eligible members adopting a preferred formulary weight loss product.” — David Joyner .

Q&A Highlights

  • Aetna visibility and conviction: Management cited strong HCB performance, with ~$300M favorable risk adjustment and favorable PYD largely offsetting the $470M group MA PDR; cautious stance on Part D given IRA changes .
  • Group MA margins and repricing: Contracts are typically 3–5 years; margin recovery may take more than one cycle; ~50% of group MA revenue up for renewal in 2026 .
  • PCW outlook: Strong prescription growth (~6.5%) and front-store sales (+3% with ~1% Easter effect); cautious on immunizations and consumer dynamics; Cost Manage on track .
  • Health Services/Oak Street: Segment guidance cut entirely due to delivery business; Oak Street pressures from elevated medical costs, member mix, and robust supplemental benefits; Signify volumes strong .
  • Part D dynamics: Standard-only plan design de-risked product for 2025; performing well; company digesting recent CMS guidance for 2026 .

Estimates Context

  • Q2 2025 beat: Adjusted EPS $1.81 vs $1.461* consensus; revenue $98.428B vs $94.594B* consensus . Q1 2025 beat: Adjusted EPS $2.25 vs $1.673*; revenue $94.068B vs $93.561B* . Values retrieved from S&P Global.
  • Guidance implies upward estimate revisions for adjusted EPS and PCW AOI, with HCB AOI raised (low end) and Health Services AOI reduced due to Oak Street; total revenue raised to ≥$391.5B .

Key Takeaways for Investors

  • Aetna recovery is the central pillar: HCB AOI up ~40% y/y; risk adjustment favorability and operations improvements support trajectory, albeit with group MA PDR indicating persistent utilization pressure .
  • Pharmacy strength offsets delivery headwinds: PCW same-store pharmacy sales +18.1% and prescriptions +6.4% drive AOI growth despite reimbursement pressure; Cost-based reimbursement transition continues .
  • Health Services margin pressure is real: Client price improvements and Oak Street MBR constrain AOI; guidance reset (-$200M) localizes the headwind to delivery .
  • Legal overhang weighed on GAAP: $833M in legacy litigation charges hit Q2; appeals are planned, but GAAP EPS guidance was lowered accordingly .
  • Raised adjusted EPS and CFO guide: FY2025 adjusted EPS $6.30–$6.40 and CFO ≥$7.5B improve visibility and support deleveraging, capital deployment, and dividend sustainability ($0.665 per share declared) .
  • Watch 2H cadence and 2026 setup: Company sees back-half earnings distribution roughly balanced in HSS with a slight tilt to Q4; 2026 group MA repricing (~50% revenue) and government reimbursement transition in PCW are key upcoming levers .
  • Trading implications: Near-term positive skew from guidance raise and Aetna momentum, tempered by Oak Street delivery risk and litigation; monitor Part D experience, GLP-1 formulary dynamics, and retention in the 2026 PBM selling season .